The Effect of Vitamin C and E Therapy on Restless Leg Syndrome in Patients With End Stage Renal Disease on Haemodialysis

End Stage Renal Disease Clinical Trial

Official title:

The Effect of Vitamin C and E Therapy on Restless Leg Syndrome in Patients With End Stage Renal Disease on Haemodialysis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05350124
• Other study ID #: VIT.C&E RLS on HM
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: November 2022
• Est. completion date: December 2023

Study information

• Verified date: August 2022
• Source: King Abdulaziz University
• Contact: Siraj Wali
• Phone: 0966505606100
• Email: sowali[@]kau.edu.sa
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to measure the effectiveness of vitamins C and E on relieving RLS symptoms in end stage renal disease patients on HD

Description:

double-blind placebo-controlled trial of 12 weeks duration on end stage renal disease (ESRD) patients on HD with RLS.

All ESRD patients on HD will be screened clinically for RLS using the five diagnostic criteria of IRLSSG by trained physicians. then the Quastioniare will be filled and inclusion and exclusion criteria be checked sleep study must be done.

Each patient will then undergo a full sleep study using level 2 polysomnography at home. Periodic leg movements with sleep (PLMs) index and leg movements index (LM) before sleep onset will be recorded as well as other variables

Then Subjects will then be randomly assigned by blocked randomization into four groups, each group will include 40 patients. A. Group 1: Will receive vitamin C (200 mg) tablet and vitamin E (a-tocopherol) (400 mg) capsule every day for 12 weeks. B. Group 2: Will receive vitamin E (400 mg) capsule and placebo every day for 12 weeks.

C. Group 3: Will receive vitamin C (200 mg) tablet and placebo every day for 12 weeks. D. Group 4: Will receive two placebo every day for 12 weeks. Of note, the personal responsible for randomization will not be involved in the trial.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 160
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• End stage renal disease patients on hemodialysis who met the five diagnostic criteria of RLS.

Exclusion Criteria:

• Secondary causes of RLS Medications (list included in section C below) iron deficiency or peripheral neuropathy

Presence of RLS-mimicking disorders:

1. Arthritis

2. Deep venous thrombosis

3. Varicose veins or venous insufficiency

4. Habitual foot tapping

Patients receiving medications that could trigger RLS:

1. Anticonvulsants, e.g., new use of anticonvulsant drugs within6 months of screening. A stable regimen of anticonvulsants was allowed.

2. Antipsychotics (haloperidol or phenothiazine derivatives)

3. Antidepressants (selective serotonin reuptake inhibitors or tricyclic antidepressants)

4. Antimanic (lithium)

Patients on medications or with conditions that may interfere with vitamin C & E absorption:

1. Celiac disease

2. Crohn's disease

3. Chronic pancreatitis

4. Cystic fibrosis

5. Weight-reduction drugs

6. Chemotherapy and radiotherapy

Patients with contraindications for vitamin C & E supplements:

1. Blood disorders, e.g., thalassemia, G6PD, sickle cell disease and hemochromatosis

2. Other conditions like diabetic patients, oxalate nephropathy, nephrolithiasis and vitamin E or C allergy

3. Unstable vital signs

4. Retinal eye disease

5. Cancers

6. Liver disease

7. Vitamin K deficiency

For women only:

1. Pregnancy (positive pregnancy test at screening)

2. Currently breastfeeding

3. Use of oral contraceptives or start of menopausal hormone therapy within 3 months of baseline

History of vitamin E or C intolerance

Related Conditions & MeSH terms

• End Stage Renal Disease
• Kidney Diseases
• Kidney Failure, Chronic
• Psychomotor Agitation
• Restless Legs Syndrome
• Syndrome

Intervention

Drug:
• Ascorbic acid
vitamin C (200 mg) capsule
• Tocopherol
vitamin E (400 IU) capsule
• Placebo capsule
Placebo one pill only
• Placebo capsule
Placebo two pills only

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
King Abdulaziz University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria	The IRLSSG is a validated and reliable questionnaire. Well-trained physicians will aid patients in completing this questionnaire and perform clinical examination. It consists of five yes/no questions, subjects will be considered to have RLS if their answers are yes to all five questions	in screening
Primary	Stop Bang	The STOP-Bang questionnaire includes the four questions used in the STOP questionnaire plus four additional demographic queries, for a total of eight dichotomous (yes/no) questions related to the clinical features of sleep apnea (snoring, tiredness, observed apnea, high blood pressure, BMI, age, neck circumference and male gender). For each question, answering "yes" scores 1, a "no" response scores 0, and the total score ranges from 0 to 8.; Low Risk: Yes to 0 - 2 questions; Intermediate Risk: Yes to 3 - 4 questions; High Risk: Yes to 5 - 8 questions; or Yes to 2 or more of 4 STOP questions + male gender; or Yes to 2 or more of 4 STOP questions + BMI > 35kg/m2; or Yes to 2 or more of 4 STOP questions + neck circumference 16 inches / 40cm	in screening
Primary	Hemoglobin	Participants with normal levels between 12 - 15 g/dl Participants with levels below 12 or above 15 will be considered abnormal	in screening
Primary	Changes in The International Restless Leg Syndrome Study Group (IRLSSG) rating scale for restless legs syndrome	That consists of 10 questions scored from 0-4 with a total score ranging from 0-40 in which RLS severity is directly proportional to the total score. Meaning the higher the score, the worse and severe the symptoms.	base line then once weekly for 12 weeks
Primary	Epworth sleepiness scale (ESS)	It is a self-administered questionnaire that measures the severity of excessive daytime sleepiness (EDS) containing 8 questions, each question is given a score from 0 to 3 with a total score of 0-24. A score above 10 is considered abnormal i.e. in keeping with EDS	base line then once every 4 weeks for 12 weeks
Primary	Medical Outcomes Study Sleep Scale (MOS)	A 12-item scale that investigates six factors including; sleep initiation, respiratory problems, maintenance, perceived adequacy and somnolence. With higher score indicating higher sleep disturbance.	base line then once every 4 weeks for 12 weeks
Primary	Suggested Immobilization Test (SIT)	prior to the sleep recording. at 45-degree angle with their legs outstretched. avoid moving voluntarily for the entire duration of the test. Surface EMG from the left and right anterior tibialis muscles is used to quantify leg movements. The latter are scored according to the criteria (movements lasting between 0.5 and 10 seconds, separated by intervals of 4 to 90 seconds and arising in series of at least 4 consecutive movements). The SIT periodic leg movements index represents the number of periodic leg movements per hour of immobility. Patients report severity of leg discomfort on a visual analogue scale (VAS) ranging from 0 (no discomfort) to 100 (extreme discomfort) every 10 minutes during the SIT. The mean leg discomfort score is assessed using the average of the 7 values, as well as the discomfort severity at the end of the test (time 60 minutes), the maximum leg discomfort during the test, and the variation between the lowest and the highest values recorded during the test	base line then once every 4 weeks for 12 weeks
Primary	Restless Leg Syndrome (RLS) Symptoms Diary	The (RLS) Symptom Diary is a convenient tool to record information on your daily (RLS) symptoms, their duration, sleep patterns and possible triggers such as nicotine, alcohol or caffeine. to identify what influences, triggers or worsen the (RLS) symptoms	base line then daily for the last 2 weeks
Primary	Polysomnography	Polysomnography (SOMNO Medics Plus; SOMNOmedics, Randersacker, Germany) consists of continuous recordings from surface leads for electroencephalography (EEG), electrooculography, electromyography (submental and bilateral anterior tibialis muscles), electrocardiography, nasal pressure, nasal and oral airflow (thermocouple), chest and abdominal impedance belts for respiratory muscle efforts, pulse oximetry for oxygen saturation and pulse rate, a tracheal microphone for snoring, and body position sensors for sleep position. PSG records are scored manually according to the American Academy of Sleep Medicine (AASM) 2020 scoring	base line then once every 4 weeks for 12 weeks
Primary	Hemoglobin A1C	Participants will be considered normal if the level is within 4.2 - 6.3 % Participants with a level higher than 6.3% will be considered abnormal	In screening
Primary	Vitamin D	Participants will be considered normal if the level is within 75 - 250 nmol/L Participants will be considered abnormal if the level is less than 75 or higher than 250 nmol/L	In screening
Primary	Serum Iron	Participants will be considered normal if the level is within 6 - 26 umol/L	In screening
Primary	Total Iron Binding Capacity	Participants will be considered normal if the level is within 25 - 92 umol/L	In screening
Primary	Ferritin	Participants will be considered normal if the level is within 13-150 ng/ml	In screening
Primary	Magnesium	Participants will be considered normal if the level is within 1.7 - 2.2 mg/dL	In screening